Home > Team
   

Shunichiro Matsumoto, Ph.D., MBA: President

Dr. Matsumoto, President of AVM, is currently serving also as a Vice President of Innovation Management at Astellas Pharma Inc., Tokyo Japan. He has 5 year experience including Investment Director of AVM at San Francisco Bay Area until 2011. He has 14 year experience in R&D specializing in molecular biology field at Astellas Pharma Inc. / Yamanouchi Pharmaceutical Co., Ltd. He received MBA from McGill University, and has PhD in Medicine from University of Tsukuba and MSc in Agriculture from Kyoto University.

 

Ryosuke Munakata, Ph.D., Executive Investment Director

Dr. Munakata joined AVM in April 2016 and covering investments in therapeutics sector. He is a medicinal chemist by training and has more than 10 years of experiences of drug discovery research in the field of pain, CNS, muscle-related disorders, and nephrology at Astellas Pharma Inc. and covers broad stage of drug discovery from pre-hit identification to preclinical development, including multiple research collaborations with external partners. His expertise as a scientist includes medicinal chemistry, structure-based drug discovery, and cheminformatics. Prior to joining AVM, he served as an Associate Director at Innovation Management, Astellas Pharma Inc., in charge of business transaction for partnering deals as well as alliance management.

 

Tadayoshi Hirata, Senior Investment Manager

Mr. Hirata Joined AVM in April 2018. Prior to Joining AVM, he worked in Innovation Management at Astellas Pharma Inc. (Japan) since April 2016, in charge of business transaction for early stage partnering deals. From June 2009 to March 2016, he worked for Clinical Pharmacology Department at Astellas Pharma Inc. taking a lead in preparing early-stage clinical development plans utilizing translational science principles. He also led clinical study protocol preparation and data analysis, and coordinated and managed preparation of applications for Clinical Pharmacology components, including Briefing Documents, INDs and NDAs and represented as a Clinical Pharmacology representative to the relevant regulatory authorities. He started his job career as a research scientist at MSD (Former Banyu Pharmaceutical co., LTD. a subsidiary of Merck & Co., Inc.) in April 2005 with background on pharmacokinetics and molecular biology.

 

Hikaru Saito, Ph.D., Senior Investment Manager

Dr. Saito joined AVM in April 2017. Prior to AVM, he worked in Innovation Management at Astellas Pharma Inc. based in Tokyo HQ since October 2015, in charge of due diligence activities for potential business partnerships. From April 2010 to September 2015, he worked as a research scientist, Pharmaceutical Research and Technology Labs. at Astellas Pharma Inc. in the field of drug formulation of oral and parenteral dosage forms. In his research position, he dedicated to formulation development including novel drug delivery system and manufacturing process development of drug products for the commercialization and also responsible for a technology development for in-house program in the field of new business beyond therapeutics through combination of drugs and medical devices. Dr. Saito received his Ph.D. in Biomolecular Engineering and a Bachelor of Engineering degree in Biotechnology from the Tokyo Institute of Technology.

 

Chihiro Hosoya, MSc, MBA: Associate Investment Director, Rx+ Business Accelerator

Ms. Hosoya joined AVM in April 2017 and is covering Rx+ opportunities. Rx+ is a healthcare solution beyond Rx business with which Astellas aims to create new revenue stream separately from our core Rx products, by combining Astellas’ capabilities with technologies from different fields. Ms. Hosoya works closely with Tokyo based Rx+ Business Accelerator team to find potential attractive opportunities for strategic collaboration either through investment or partnership. She has more than 10 years of experience in Astellas during which she developed her main career in Business Development. She received MSc in Waseda University and MBA from Tsukuba University.

 

Takuya Nojima, Ph.D., Senior Investment Manager, Rx+ Business Accelerator

Dr. Nojima Joined AVM in October 2016 and is covering Rx+ opportunities. Rx+ is a healthcare solution beyond Rx business with which Astellas aims to create new revenue stream separately from our core Rx products, by combining Astellas’ capabilities with technologies from different fields. He works closely with Tokyo based Rx+ Business Accelerator team to find potential attractive opportunities for strategic collaboration either through investment or partnership. Prior to joining AVM, he worked as a member of New Business Incubator team in Corporate Planning and a researcher in the field of ophthalmology at Drug Discovery Research Center (2014 – 2016). Prior to joining Astellas Pharma, he worked at Tokyo University of Science as an Assistant Professor (2006 – 2011) and at Duke University as a postdoctoral associate (2011 – 2014), where he contributed to the several important studies in immunology utilizing his unique methodologies.

 

 
Copyright © 2005 - 2016 Astellas Venture Management. Site Map   Privacy Policy   Legal Disclaimer   Contact Us